Search 

NanoSmart has developed and patented, a targeted drug delivery platform using human-derived, autoimmune antibodies capable of targeting many different kinds of tumors.  NanoSmart’s antitumor antibody, is not tumor-marker specific, but rather targets the areas of necrosis present in all solid tumors; including breast, lung, prostate, and rare cancers like Ewing’s Sarcoma.  Normal tissues do not have areas of necrosis and are not targeted.

NanoSmart is encapsulating off-patent FDA-approved drugs within liposomes coated with NanoSmart’s human-derived antibodies, thus creating an immunoliposome.  The liposome that encloses the active pharmaceutical ingredient protects healthy tissues while traveling to its target, and then slowly releases the drug over time.  NanoSmart’s antibody will then bind to the necrotic areas present in the middle of solid tumors and at the surrounding tumor site.

The end-result of using NanoSmart’s platform is a superior safety and efficacy profile for any drug that is adapted to our system.  Many different formulations can be developed by simply replacing one drug with another.  Each formulation is novel, patentable, and non-tumor specific (i.e. targets multiple cancers), and can be developed at a fraction of the cost and time typically associated with new drug development (i.e. IND to NDA in approximately 2-3 years).

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar is well-respected as a partner-of-choice with the world's leading pharmaceutical and biotechnology companies. Our platform technologies are validated and used in many of today's top-selling commercial drugs. As a result, industry returns to us time and time again to co-develop the next-generation of successful drugs designed to meet critical unmet medical needs.

Our strategic partnerships range from joint discovery and co-development to licensing and royalty arrangements with a wide range of organizations.

Vice President, Licensing and M&A

Principia Biopharma is building an integrated pharmaceutical company focused on the discovery and development of reversible covalent drugs for the treatment of autoimmune diseases and cancer.  Principia’s reversible covalent technology, which has been validated in vivo against multiple targets to date, produces molecules with superior attributes and our approach has significant advantages over standard drug development methods. 

o   It produces highly potent (low nanomolar to picomolar) compounds with increased selectivity and prolonged durability despite limited exposure.

o   Accelerates the drug development process by avoiding the need for HTS and the  provides the opportunity to evolve tool compounds into clinical candidates

o   Has a broad range of applicability across multiple target classes

Given the wealth of opportunities addressable with Principia’s technology, the company is interested in working with partners to fully exploit the technology outside of cancer and autoimmune therapeutic areas.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, oncology, as well as muscle disorders.  Partnering projects include: 1) R763 an Aurora Kinase inhibitor for oncology with Phase 2 results and 2)  R723 a selective Jak2 inhibitor in preclinical development for Thrombocytosis in RA, RA, and Myeloproliferative Diseases (hematology). 

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract).

Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world’s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter's lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company has constructed antibody libraries containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets.

Our strategy is to selectively collaborate with leading companies with the resources and capabilities to assist us in developing and commercializing some of our product candidates, particularly in target indications for which our collaborator has significant expertise or that involve large primary care markets. We generally seek co-promotion or co-commercialization rights in alliances.

We have a collaboration with AstraZeneca focused in cognitive disorders that includes AZD-3480 and AZD-1446.  We have the option to co-promote  certain compounds licensed under our cognitive disorders agreement to selected specialist physicians in the US.

 We are currently interested in exploring alliances or collaborations for:

• TC-5619, which is in on-going Phase 2 trials in negative symptoms of schizophrenia and ADHD predominantly inattentive subtype; • TC-6499, which in a Phase 2a study showed encouraging potential to enhance GI motility relevant to treating GI/GU disorders such as diabetic gastroparesis and IBS-C/CIC; and • Targacept’s Parkinson’s disease/levodopa-induced dyskinesia program to exploit NNR Therapeutics for symptomatic treatment and disease modification.

We are receptive to evaluating clinical-stage CNS, GI/GU or Orphan opportunities to complement our pipeline.